stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) Book value per share
Arcutis Biotherapeutics, Inc.'s book value per share at the end of fiscal 2025 was 1.5×, up 14.3% from 1.3× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 1.9×. Over the past ten years it has ranged from −35.3× (fiscal 2019) to 7.6× (fiscal 2020); the current reading is higher than 67% of that period. Arcutis Biotherapeutics, Inc. ranks 477th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 1.5× | 14.34% |
| FY2024 | 1.3× | 1.80% |
| FY2023 | 1.3× | (66.40%) |
| FY2022 | 3.8× | (36.79%) |
| FY2021 | 6.0× | (20.59%) |
| FY2020 | 7.6× | — |
| FY2019 | −35.3× | — |
| FY2018 | −19.3× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 1.9× | 10.19% |
| Jun 2026 | 1.7× | 15.28% |
| Mar 2026 | 1.5× | (1.56%) |
| Dec 2025 | 1.5× | 20.23% |
| 29 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| DNTH Dianthus Therapeutics, Inc. compare | 21.6× |
| DFTX Definium Therapeutics, Inc. compare | 8.3× |
| TNGX Tango Therapeutics, Inc. compare | 6.8× |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 6.6× |
| RLAY Relay Therapeutics, Inc. compare | 4.4× |
| EWTX Edgewise Therapeutics, Inc. compare | 4.2× |
| ABCL AbCellera Biologics Inc. compare | 2.9× |
| ARQT Arcutis Biotherapeutics, Inc. | 0.0× |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement